Drug maker Pfizer is planning to extend its Corex brand to a series of new products to treat respiratory ailments as part of a revamp of its product portfolio. The company has also decided to ...

REUTERS - Delhi High Court granted U.S. drugmaker Pfizer an interim injunction on a ban on its popular cough syrup Corex, days after the government ordered it to be prohibited citing a potential risk ...

Pfizer Q4 results: The company's standalone total income from operations rose to Rs 515.1 crore for the quarter under review as against Rs 463.1 crore a year ago. In a relief to pharma major Pfizer ...

Corex is a combination of chlopheniramine maleate and codeine syrup -- one of 344 drug combinations India banned over the weekend after a government panel of experts found they had "no therapeutic ...

Pfizer is planning to extend its Corex brand to a series of new products to treat respiratory ailments as part of a revamp of its product portfolio. The company has also decided to discontinue the ...

New Delhi: Pharmaceutical major Pfizer has discontinued manufacture and sale of popular cough syrup Corex with immediate effect after the government banned fixed dose combination of Chlopheniramine ...

Pharmaceutical company Pfizer has with immediate effect stopped making and selling cough syrup Corex in India after the government prohibited fixed dose combination of Chlopheniramine Maleate + ...

The Delhi High Court granted an interim stay of a notification restraining sale of pharma major Pfizer's cough syrup Corex, and directed the government not to take coercive steps against the company.

Pfizer Inc's India unit said on Monday it had stopped selling its popular Corex cough syrup, after regulators banned it saying it was likely to pose a risk to humans. (Reuters Photo) Mumbai: US ...

Drug maker Pfizer has decided to discontinue the manufacturing of Corex cough syrup. New Delhi: Drug maker Pfizer is planning to extend its Corex brand to a series of new products to treat respiratory ...